Does the media favor MNKD or BCRX?

In the previous week, MannKind had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 6 mentions for MannKind and 5 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.79 beat MannKind's score of 0.25 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioCryst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, MNKD or ZBIO?

MannKind has higher revenue and earnings than Zenas BioPharma. MannKind is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $348.97M 3.62 $5.86M -$0.07 N/A Zenas BioPharma $10M 181.44 -$377.74M -$8.47 N/A

Does the media favor MNKD or ZBIO?

In the previous week, MannKind had 2 more articles in the media than Zenas BioPharma. MarketBeat recorded 6 mentions for MannKind and 4 mentions for Zenas BioPharma. MannKind's average media sentiment score of 0.25 beat Zenas BioPharma's score of 0.00 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, MNKD or INVA?

Innoviva has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $348.97M 3.62 $5.86M -$0.07 N/A Innoviva $411.33M 3.99 $271.17M $6.01 3.70

Is MNKD or INVA more profitable?

Innoviva has a net margin of 119.89% compared to MannKind's net margin of -6.63%. Innoviva's return on equity of 33.33% beat MannKind's return on equity. Company Net Margins Return on Equity Return on Assets MannKind -6.63% -11.21% -3.92% Innoviva 119.89% 33.33% 22.67%

Does the media favor MNKD or INVA?

In the previous week, MannKind had 3 more articles in the media than Innoviva. MarketBeat recorded 6 mentions for MannKind and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.11 beat MannKind's score of 0.25 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Innoviva 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, NVAX or MNKD?

Novavax has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.37 $440.30M -$0.58 N/A MannKind $348.97M 3.62 $5.86M -$0.07 N/A

Is NVAX or MNKD more profitable?

MannKind has a net margin of -6.63% compared to Novavax's net margin of -14.73%. MannKind's return on equity of -11.21% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% MannKind -6.63% -11.21% -3.92%

Does the media prefer NVAX or MNKD?

In the previous week, Novavax had 16 more articles in the media than MannKind. MarketBeat recorded 22 mentions for Novavax and 6 mentions for MannKind. Novavax's average media sentiment score of 0.71 beat MannKind's score of 0.25 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 6 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive MannKind 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MannKind (MNKD) Competitors

$4.09 -0.05 (-1.21%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$4.06 -0.03 (-0.83%)

As of 07/10/2026 07:58 PM Eastern

Compare

MNKD vs. CLDX, BCRX, ZBIO, INVA, and NVAX

Should you buy MannKind stock or one of its competitors? MarketBeat compares MannKind with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MannKind include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Zenas BioPharma (ZBIO), Innoviva (INVA), and Novavax (NVAX). These companies are all part of the "biotechnology" industry.

How does MannKind compare to Celldex Therapeutics?

MannKind (NASDAQ:MNKD) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

MannKind has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

Celldex Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Celldex Therapeutics	N/A	-50.72%	-46.59%

In the previous week, MannKind had 5 more articles in the media than Celldex Therapeutics. MarketBeat recorded 6 mentions for MannKind and 1 mentions for Celldex Therapeutics. MannKind's average media sentiment score of 0.25 beat Celldex Therapeutics' score of 0.00 indicating that MannKind is being referred to more favorably in the media.

Company	Overall Sentiment
MannKind	Neutral
Celldex Therapeutics	Neutral

MannKind has higher revenue and earnings than Celldex Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.62	$5.86M	-$0.07	N/A
Celldex Therapeutics	$1.54M	1,993.34	-$258.76M	-$4.26	N/A

49.6% of MannKind shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MannKind presently has a consensus target price of $8.97, suggesting a potential upside of 119.28%. Celldex Therapeutics has a consensus target price of $49.30, suggesting a potential upside of 26.05%. Given MannKind's higher possible upside, analysts clearly believe MannKind is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

MannKind beats Celldex Therapeutics on 10 of the 17 factors compared between the two stocks.

How does MannKind compare to BioCryst Pharmaceuticals?

MannKind (NASDAQ:MNKD) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

MannKind has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

MannKind has a net margin of -6.63% compared to BioCryst Pharmaceuticals' net margin of -51.71%. MannKind's return on equity of -11.21% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

In the previous week, MannKind had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 6 mentions for MannKind and 5 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.79 beat MannKind's score of 0.25 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind presently has a consensus target price of $8.97, indicating a potential upside of 119.28%. BioCryst Pharmaceuticals has a consensus target price of $21.78, indicating a potential upside of 108.40%. Given MannKind's higher possible upside, equities analysts clearly believe MannKind is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

49.6% of MannKind shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 2.6% of MannKind shares are held by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioCryst Pharmaceuticals has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.62	$5.86M	-$0.07	N/A
BioCryst Pharmaceuticals	$885.72M	3.00	$263.86M	-$1.78	N/A

Summary

BioCryst Pharmaceuticals beats MannKind on 9 of the 16 factors compared between the two stocks.

How does MannKind compare to Zenas BioPharma?

MannKind (NASDAQ:MNKD) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

MannKind has higher revenue and earnings than Zenas BioPharma. MannKind is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.62	$5.86M	-$0.07	N/A
Zenas BioPharma	$10M	181.44	-$377.74M	-$8.47	N/A

MannKind presently has a consensus target price of $8.97, indicating a potential upside of 119.28%. Zenas BioPharma has a consensus target price of $44.29, indicating a potential upside of 54.09%. Given MannKind's higher probable upside, equities research analysts plainly believe MannKind is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, MannKind had 2 more articles in the media than Zenas BioPharma. MarketBeat recorded 6 mentions for MannKind and 4 mentions for Zenas BioPharma. MannKind's average media sentiment score of 0.25 beat Zenas BioPharma's score of 0.00 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zenas BioPharma has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Zenas BioPharma	N/A	-99.99%	-58.06%

49.6% of MannKind shares are held by institutional investors. 2.6% of MannKind shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MannKind has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.96, suggesting that its share price is 196% less volatile than the broader market.

Summary

MannKind beats Zenas BioPharma on 11 of the 16 factors compared between the two stocks.

How does MannKind compare to Innoviva?

MannKind (NASDAQ:MNKD) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

In the previous week, MannKind had 3 more articles in the media than Innoviva. MarketBeat recorded 6 mentions for MannKind and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.11 beat MannKind's score of 0.25 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a net margin of 119.89% compared to MannKind's net margin of -6.63%. Innoviva's return on equity of 33.33% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Innoviva	119.89%	33.33%	22.67%

Innoviva has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.62	$5.86M	-$0.07	N/A
Innoviva	$411.33M	3.99	$271.17M	$6.01	3.70

MannKind presently has a consensus price target of $8.97, indicating a potential upside of 119.28%. Innoviva has a consensus price target of $36.20, indicating a potential upside of 62.77%. Given MannKind's higher probable upside, equities research analysts plainly believe MannKind is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

MannKind has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

49.6% of MannKind shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 2.0% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Innoviva beats MannKind on 11 of the 16 factors compared between the two stocks.

How does MannKind compare to Novavax?

Novavax (NASDAQ:NVAX) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

MannKind has a net margin of -6.63% compared to Novavax's net margin of -14.73%. MannKind's return on equity of -11.21% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
MannKind	-6.63%	-11.21%	-3.92%

Novavax currently has a consensus target price of $13.00, suggesting a potential upside of 39.34%. MannKind has a consensus target price of $8.97, suggesting a potential upside of 119.28%. Given MannKind's stronger consensus rating and higher possible upside, analysts plainly believe MannKind is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

53.0% of Novavax shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Novavax has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.37	$440.30M	-$0.58	N/A
MannKind	$348.97M	3.62	$5.86M	-$0.07	N/A

Novavax has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market. Comparatively, MannKind has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

In the previous week, Novavax had 16 more articles in the media than MannKind. MarketBeat recorded 22 mentions for Novavax and 6 mentions for MannKind. Novavax's average media sentiment score of 0.71 beat MannKind's score of 0.25 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
MannKind	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Novavax beats MannKind on 9 of the 17 factors compared between the two stocks.

Get MannKind News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNKD vs. The Competition

Export

Metric	MannKind	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.28B	$3.78B	$7.12B	$12.61B
Dividend Yield	N/A	2.17%	2.68%	7.83%
P/E Ratio	-58.42	21.27	27.19	24.56
Price / Sales	3.62	323.90	591.20	121.87
Price / Cash	66.90	147.64	49.34	60.04
Price / Book	-24.06	8.41	10.88	6.39
Net Income	$5.86M	$23.85M	$3.58B	$331.76M
7 Day Performance	-9.51%	-0.75%	-0.27%	0.37%
1 Month Performance	9.07%	8.81%	4.51%	0.53%
1 Year Performance	8.49%	53.62%	29.15%	21.93%

MannKind Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNKD MannKind	3.8349 of 5 stars	$4.09 -1.2%	$8.97 +119.3%	+7.6%	$1.28B	$348.97M	N/A	400	News Coverage Analyst Downgrade
CLDX Celldex Therapeutics	1.7981 of 5 stars	$37.95 -1.1%	$49.30 +29.9%	+72.4%	$3.01B	$1.54M	N/A	150
BCRX BioCryst Pharmaceuticals	3.1323 of 5 stars	$10.17 +3.4%	$21.67 +113.0%	+17.7%	$2.50B	$874.84M	N/A	530	News Coverage Analyst Forecast
ZBIO Zenas BioPharma	3.1653 of 5 stars	$26.45 -2.9%	$44.29 +67.4%	+138.1%	$1.72B	$10M	N/A	N/A	News Coverage Analyst Downgrade
INVA Innoviva	3.6625 of 5 stars	$21.82 -2.2%	$36.20 +65.9%	+16.7%	$1.65B	$411.33M	3.63	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNKD) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MannKind (MNKD) Competitors

MNKD vs. CLDX, BCRX, ZBIO, INVA, and NVAX

How does MannKind compare to Celldex Therapeutics?

Summary

How does MannKind compare to BioCryst Pharmaceuticals?

Summary

How does MannKind compare to Zenas BioPharma?

Summary

How does MannKind compare to Innoviva?

Summary

How does MannKind compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MannKind (MNKD) Competitors

MNKD vs. CLDX, BCRX, ZBIO, INVA, and NVAX

How does MannKind compare to Celldex Therapeutics?

Which has more volatility and risk, MNKD or CLDX?

Is MNKD or CLDX more profitable?

Does the media prefer MNKD or CLDX?

Which has stronger earnings and valuation, MNKD or CLDX?

Do insiders & institutionals hold more shares of MNKD or CLDX?

Do analysts recommend MNKD or CLDX?

Summary

How does MannKind compare to BioCryst Pharmaceuticals?

Which has more risk and volatility, MNKD or BCRX?

Is MNKD or BCRX more profitable?

Does the media favor MNKD or BCRX?

Do analysts prefer MNKD or BCRX?

Do institutionals and insiders believe in MNKD or BCRX?

Which has higher valuation and earnings, MNKD or BCRX?

Summary

How does MannKind compare to Zenas BioPharma?

Which has preferable valuation and earnings, MNKD or ZBIO?

Do analysts recommend MNKD or ZBIO?

Does the media favor MNKD or ZBIO?

Is MNKD or ZBIO more profitable?

Do insiders & institutionals believe in MNKD or ZBIO?

Which has more volatility and risk, MNKD or ZBIO?

Summary

How does MannKind compare to Innoviva?

Does the media favor MNKD or INVA?

Is MNKD or INVA more profitable?

Which has preferable earnings and valuation, MNKD or INVA?

Do analysts rate MNKD or INVA?

Which has more risk and volatility, MNKD or INVA?

Do insiders and institutionals believe in MNKD or INVA?

Summary

How does MannKind compare to Novavax?

Is NVAX or MNKD more profitable?

Do analysts rate NVAX or MNKD?

Do institutionals and insiders hold more shares of NVAX or MNKD?

Which has stronger valuation and earnings, NVAX or MNKD?

Which has more volatility & risk, NVAX or MNKD?

Does the media prefer NVAX or MNKD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools